This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Yangtianhe Pharmacy Co., Ltd. signed Share Transfer Agreement to acquire 7% stake in Guangdong Jiaying Pharmaceutical Co., Ltd from Chen Shaobin for approximately CNY 360 million. CI
Huang Junjie completed the acquisition of 5.03% stake in Guangdong Jiaying Pharmaceutical Co., Ltd from Liu Libiao. CI
Huang Junjie completed the acquisition of 5.03% stake in Guangdong Jiaying Pharmaceutical Co., Ltd from Liu Libiao. CI
Huang Junjie signed share transfer agreement to acquire 5.03% stake in Guangdong Jiaying Pharmaceutical Co., Ltd from Liu Libiao for CNY 230 million. CI
Guangdong Jiaying Pharmaceutical Co., Ltd Approves Final Cash Dividend for the Year 2023 on A Shares, Payable on 21 June 2024 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Announcement of Resolutions of Guangdong Jiaying?s Fifth Extraordinary General Meeting of Shareholders in 2021 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangdong Jiaying Pharmaceutical Co., Ltd. Approves Management Appointments CI
Resolutions on Supervisor Nomination by Guangdong Jiaying Venture Capital CI
Guangdong Jiaying Venture Capital Submits Proposals Related to Supervisor Nominations CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guangzhou Taiping Enterprise Management Partnership (Limited Partnership) signed the Share Transfer Agreement to acquire 5% stake in Guangdong Jiaying Pharmaceutical Co., Ltd from Chen Shaobin for approximately CNY 195 million. CI
Jiaying Pharma Sees Up to 3,420% Surge in 2022 Profit MT
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Jiaying Pharmaceutical’s Profit Crashes 93% in 2021 Despite Revenue Growth MT
Guangdong Jiaying Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Liu Libiao completed the acquisition of 5.03% stake in Guangdong Jiaying Pharmaceutical Co., Ltd from Huang Zhiyong and Huang Libing. CI
Chen Shaobin completed the acquisition of 10% stake in Guangdong Jiaying Pharmaceutical Co., Ltd from Chen Yonghong. CI
Liu Libiao agreed to acquire 5.03% stake in Guangdong Jiaying Pharmaceutical Co., Ltd from Huang Zhiyong and Huang Libing for approximately CNY 210 million. CI
Chart Guangdong Jiaying Pharmaceutical Co., Ltd
More charts
GUANGDONG JIAYING PHARMACEUTICAL CO., LTD is a China-based company principally engaged in the research, development, manufacture and sales of Chinese patent medicine. The Company’s main products include Chinese traditional preparations, powders, tablets, capsules and granules, which are mainly applied in the treatment of throat disease, cold, stomach disease and others, as well as for tonic nourish purpose and others. The Company distributes its products mainly in domestic market. Through its subsidiaries, the Company is also engaged in the operation and leasing of self-owned real estate.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002198 Stock
  4. News Guangdong Jiaying Pharmaceutical Co., Ltd
  5. Jiaying Pharmaceutical’s Profit Crashes 93% in 2021 Despite Revenue Growth